AD Neural Stem Cell and Progenitor Cell Therapy Companies

Alzheimer's Disease Neural Stem Cell and Progenitor Cell Therapy Companies

Overview

Alzheimer's Disease Neural Stem Cell and Progenitor Cell Therapy Companies

Overview

This page catalogs biotechnology and pharmaceutical companies developing neural stem cell (NSC) and neural progenitor cell (NPC) therapies for Alzheimer's disease (AD). These approaches represent a distinct category within regenerative medicine, focusing specifically on:

This differs from broader cell therapy approaches (covered in [AD Cell Therapy Companies](/companies/ad-cell-therapy-companies)) by specifically targeting the neural stem/progenitor cell compartment within the neurogenic niches of the adult brain.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| Exogenous NSC Transplantation | Direct delivery of neural stem cells to replace lost neurons | Nostro Therapeutics, Neuralstem |
| iPSC-Derived NPCs | Patient-specific neural progenitors from iPSCs | Neurowonder, Cellize, StemoniX, Anagenesis |
| Endogenous NSC Activation | Stimulate own NSC pools in SVZ and hippocampus | ReProCells, Neurosphere |

Exogenous Neural Stem Cell Transplantation

Nostro Therapeutics

Status: Preclinical

Nostro Therapeutics is focused on developing neural stem cell-based therapies for neurodegenerative diseases. Their approach involves proprietary NSC lines engineered for optimal survival, integration, and功能性 in the AD brain.

• Cell Source: Allogeneic neural stem cells
• Target: Hippocampal and cortical neurons
• Mechanism: Cell replacement, neurotrophic factor secretion, synaptic integration
• Delivery: Intracerebral or intrathecal administration
• Status: Preclinical development

Neuralstem, Inc.

Status: Discovery (AD)

Neuralstem pioneered the development of neural stem cell therapies and has advanced NSI-566, a human neural stem cell line, through clinical trials for stroke and ALS. The company is exploring applications in AD.

• Product: NSI-566 (human neural stem cells)
• Mechanism: Neurotrophic factor secretion (BDNF, NGF, GDNF), stimulation of endogenous neurogenesis
• Target: Replace degenerated neurons in hippocampus and cortex
• Delivery: Intracerebral implantation
• Status: Discovery stage for AD

iPSC-Derived Neural Progenitor Cell Therapies

Neurowonder

Status: Preclinical

Neurowonder is developing patient-specific iPSC-derived neural progenitor cell (NPC) therapies for AD. Their platform focuses on generating NPCs that can differentiate into cholinergic neurons to restore basal forebrain function.

• Cell Source: Autologous iPSC-derived neural progenitors
• Target: Basal forebrain cholinergic neurons
• Advantage: Patient-specific, reducing immune rejection risk
• Mechanism: Neuronal replacement, circuit reconstruction
• Status: Preclinical

Cellize

Status: Preclinical

Cellize specializes in scalable iPSC-derived neural cell manufacturing. Their platform produces high-quality NPCs and neurons for AD therapy applications, with a focus on consistent, bankable cell products.

• Platform: Scalable iPSC differentiation to NPCs
• Cell Types: Neural progenitors, cortical neurons, cholinergic neurons
• Advantage: Consistent manufacturing, scalable production
• Status: Preclinical

StemoniX

Status: Preclinical

StemoniX provides iPSC-derived neural cells for disease modeling and therapeutic development. Their microbrain® and other platforms enable scalable production of neural cells for AD applications.

• Products: microbrain® 3D neural cultures, NPCs, neurons
• Platform: Scalable hiPSC-derived neural cells
• Applications: Disease modeling, drug screening, therapy development
• Status: Preclinical AD program

Anagenesis

Status: Preclinical

Anagenesis is developing allogeneic iPSC-derived neural progenitor cell therapies for AD. Their immuno-evasive NPC lines are designed to avoid immune rejection, enabling off-the-shelf allogeneic products.

• Cell Source: Allogeneic iPSC-derived NPCs
• Platform: Hypoimmunogenic NPC lines
• Advantage: Ready-to-use allogeneic product, reduced immunosuppression
• Status: Preclinical

Endogenous NSC Activation Approaches

ReProCells

Status: Discovery

ReProCells focuses on activating the brain's endogenous neural stem cell populations for regeneration. Their small molecule approach aims to stimulate neurogenesis in the subventricular zone (SVZ) and dentate gyrus.

• Approach: Small molecule NSC activators
• Target: SVZ and hippocampal neurogenic niches
• Mechanism: Promote NSC proliferation and neuronal differentiation
• Status: Discovery

Neurosphere

Status: Preclinical

Neurosphere develops biologics and small molecules that expand and direct endogenous neural stem cell differentiation. Their platform targets the neurogenic niches to promote neuronal replacement in AD.

• Products: NSC-expanding compounds, lineage-directing biologics
• Target: Endogenous NSC pools in SVZ and dentate gyrus
• Mechanism: NSC proliferation, neuronal differentiation bias
• Status: Preclinical

Company Summary Table

| Company | Approach | Development Stage | Cell Source |
|---------|----------|-------------------|-------------|
| Nostro Therapeutics | NSC Transplantation | Preclinical | Allogeneic NSCs |
| Neuralstem | NSC Transplantation | Discovery | Human neural stem cells |
| Neurowonder | iPSC-Derived NPCs | Preclinical | Autologous iPSCs |
| Cellize | iPSC-Derived NPCs | Preclinical | Allogeneic iPSCs |
| StemoniX | iPSC-Derived NPCs | Preclinical | hiPSC-derived |
| Anagenesis | iPSC-Derived NPCs | Preclinical | Allogeneic iPSCs |
| ReProCells | Endogenous Activation | Discovery | N/A (small molecules) |
| Neurosphere | Endogenous Activation | Preclinical | N/A (biologics) |

Comparison with Related Approaches

This category focuses specifically on NSC/NPC therapies. Related approaches include:

• [AD Cell Therapy Companies](/companies/ad-cell-therapy-companies) — Broader cell therapy including MSC, ESC-derived, and other cell types
• [AD Neurogenesis Companies](/companies/ad-neurogenesis-companies) — Companies targeting neurogenesis through various mechanisms including small molecules and neurotrophic factors
• [iPSC Therapy](/technologies/stem-cells) — Technology platform for generating patient-specific cells

Clinical Considerations

Neurogenic Niches

The two primary neurogenic niches in the adult human brain:

Therapeutic NSC/NPC approaches target these regions for maximal integration.

Challenges

• Survival and Integration — Ensuring transplanted cells survive and form appropriate synapses
• Tumorigenicity Risk — Careful characterization to prevent undifferentiated cell contamination
• Immune Rejection — Allogeneic cells require immunosuppression; autologous iPSC approaches avoid this
• Delivery — CNS delivery requires careful consideration of routes (intracerebral, intrathecal, intravenous)
• Functional Integration — Cells must integrate into existing neural circuits

References